Philipp Spycher has an extensive background in bioconjugation and ADCs. He obtained his master’s degree and Ph.D. from ETH Zurich in material science and protein engineering. During his post-doctoral work at Paul Scherrer Institute, he introduced the novel approach of using transglutaminases for antibody conjugation, which led to the discovery of what is now called Araris linker technology.

Meanwhile, Aphaia Pharma is also developing a promising drug candidate for weight loss, APH-012, with a focus on why L-cells – nutrient-sensing cells in the distal part of the intestine – in patients with metabolic disease are largely deprived from contact with food, as this leads to a lack of endocrine, neuroendocrine, and neuronal stim

Ambrx is the pioneer of an expanded genetic code technology platform for synthetic amino acid incorporation into proteins at any position, providing a unique

Xalud is using a non-viral DNA plasmid vector to restore homeostasis and treat pathologic inflammation within the immune system. Howard Rutman, M.D., MBA, Chief Medical Officer at Xalud Therapeutics

Switzerland-based Aphaia Pharma, in May launched its Phase II clinical trial of its daily glucose formulation, which is taken mixed with water. It curbs appetite by restoring the natural release of GLP-1 and other hormones, without causing nausea, Phase I data showed.

Tessera Therapeutics–a biotechnology startup based in Somerville, Massachusetts–followed with more modest flair: a simple banner, a speaker, and about 30 team members.

In MindMed’s LSD trial in Fort Collins, some groups are excluded from participation: pregnant women and people with a history of psychosis. That’s because the risks of using psychedelics in these populations are not fully understood.

The combination of large-scale biological datasets and developments in artificial intelligence (AI) has revolutionized our understanding and treatment of central nervous system (CNS) disorders.